- Home
- CSTL vs VSTM Comparison
CSTL vs VSTM Comparison
Compare CSTL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- VSTM
- Stock Information
- Founded
- CSTL 2007
- VSTM 2010
- Country
- CSTL United States
- VSTM United States
- Employees
- CSTL N/A
- VSTM N/A
- Industry
- CSTL Medical Specialities
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- CSTL Health Care
- VSTM Health Care
- Exchange
- CSTL Nasdaq
- VSTM Nasdaq
- Market Cap
- CSTL 456.2M
- VSTM 425.9M
- IPO Year
- CSTL 2019
- VSTM 2012
- Fundamental
- Price
- CSTL $18.52
- VSTM $4.93
- Analyst Decision
- CSTL Strong Buy
- VSTM Strong Buy
- Analyst Count
- CSTL 6
- VSTM 8
- Target Price
- CSTL $37.67
- VSTM $12.71
- AVG Volume (30 Days)
- CSTL 419.5K
- VSTM 2.6M
- Earning Date
- CSTL 08-04-2025
- VSTM 08-07-2025
- Dividend Yield
- CSTL N/A
- VSTM N/A
- EPS Growth
- CSTL N/A
- VSTM N/A
- EPS
- CSTL N/A
- VSTM N/A
- Revenue
- CSTL $347,083,000.00
- VSTM $10,000,000.00
- Revenue This Year
- CSTL N/A
- VSTM $129.06
- Revenue Next Year
- CSTL $1.36
- VSTM $306.32
- P/E Ratio
- CSTL N/A
- VSTM N/A
- Revenue Growth
- CSTL 38.43
- VSTM N/A
- 52 Week Low
- CSTL $15.45
- VSTM $2.10
- 52 Week High
- CSTL $35.84
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- CSTL 56.09
- VSTM 30.80
- Support Level
- CSTL $17.89
- VSTM $5.73
- Resistance Level
- CSTL $19.38
- VSTM $6.62
- Average True Range (ATR)
- CSTL 0.82
- VSTM 0.46
- MACD
- CSTL 0.26
- VSTM -0.17
- Stochastic Oscillator
- CSTL 77.46
- VSTM 0.84
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.